SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison.

In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough. He emphasizes that early detection through rapid diagnostic testing, combined with data-driven surveillance and practical prevention measures, can help keep students healthy and in school.
Key points from Dr. Temte's discussion include:
This episode reflects QuidelOrtho's commitment to equipping healthcare providers and the public with timely, actionable information. By highlighting expert insights and practical solutions, QuidelOrtho aims to reduce illness spread and safeguard community health.
The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader, developing and manufacturing intelligent in vitro diagnostics solutions that transform data into understanding and action for more people in more places every day.
By offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, QuidelOrtho brings fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$20.35 |
| Daily Change: | -0.91 -4.28 |
| Daily Volume: | 4,380,763 |
| Market Cap: | US$1.380B |
November 05, 2025 November 03, 2025 September 22, 2025 August 19, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load